![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Citius Pharmaceuticals Co-Founder and CEO Discusses the Recently Accepted Biologics License Application of Lymphir for the Treatment of Relapsed/Refractory CTCL
admin June 28, 2024 ArticleIn an interview with Pharm Exec Associate Editor Don Tracy, Leonard Mazur, Co-founder, CEO, Citius Pharmaceuticals, offers an update on the recently accepted Biologics License Application for Lymphir by the FDA and other candidates currently in the Citius pipeline.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
FDA Issues Complete Response Letter to Merck and Daiichi Sankyo for Patritumab Deruxtecan for Advanced, Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
admin June 28, 2024 ArticleThe Complete Response Letter was issued as a result of inspection findings at a third-party manufacturing facility, unrelated to patritumab deruxtecan’s efficacy or safety in patients with advanced or metastatic EGFR-mutated non-small cell lung cancer.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Citius Pharmaceuticals Co-Founder and CEO Talks Promising Results from a Phase III Clinical Trial for Mino-Lok, a Treatment Designed to Salvage Catheters in Patients with Central-Line Associated Infections
admin June 27, 2024 ArticleIn an interview with Pharm Exec Associated Editor Don Tracy, Leonard Mazur, Co-Founder, CEO, Citius Pharmaceuticals, discusses recent topline results from the pivotal Phase III Clinical Trial of Mino-Lok, which works to salvage catheters infections.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
FDA Accepts Otsuka and Lundbeck’s Supplemental New Drug Application for Brexpiprazole to Treat Adults with Post-Traumatic Stress Disorder
admin June 27, 2024 ArticleResults from three randomized clinical trials show safety and efficacy of a brexpiprazole-sertraline combination in adult patients with post-traumatic stress disorder.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Pharma Pulse 6/26/24: Empowering Women in Pharmacy, AI is Helping Scammers & more
admin June 26, 2024 ArticleThe latest news for pharma industry insiders.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Novo Nordisk to Invest $4.1 Billion in Expanding Manufacturing Capabilities in the United States
admin June 26, 2024 ArticleInvestment is expected to fund a new fill and finish manufacturing facility to enhance production of injectable treatments for obesity and chronic diseases.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Not Just Another Tactic: Why Pharmaceutical Brands Need to Build a Strategy Around Point of Care Messaging
admin June 25, 2024 ArticlePoint of care messaging offers unique advantages in pharmaceutical marketing and should be a high priority in brand strategy discussions.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
FDA Approves Harmony Biosciences’ Wakix to Treat Excessive Daytime Sleepiness in Pediatric Patients with Narcolepsy
admin June 25, 2024 ArticleApproval of Wakix marks the first time a non-scheduled treatment option for excessive daytime sleepiness has been approved for patients ages 6 years and older.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
NABIP Launches 2025 Medicare and Medicare Advantage Compliance Certification
admin June 24, 2024 ArticleThe online program is required for brokers and agents to sell Medicare Advantage Plans.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Novel Therapy Shows Significant Promise Slowing Parkinson Disease Progression
admin June 24, 2024 ArticleData from an early phase trial published in Nature found that Parkinson disease patients treated with UB-312 experienced significant improvements in motor functions and daily living.